Enfermedades infecciosas y del sistema inmunitario

Infección por el VIH y farmacocinética de antivirales

Luis Fernando López Cortés
Luis Fernando López Cortés
IBiS
Campus Hospital Universitario Virgen del Rocío
Avda. Manuel Siurot, s/n.
41013 · Sevilla

Laboratorio: 213
Ezequiel Ruiz-Mateos Carmona
Ezequiel Ruiz-Mateos Carmona
IBiS
Campus Hospital Universitario Virgen del Rocío
Avda. Manuel Siurot, s/n.
41013 · Sevilla
Laboratorio: 211

Luis Fernando López Cortés

Volver al programa
  1. Miembros del grupo
  2. Áreas de trabajo
  3. Publicaciones

Grupo: Infección por el VIH y farmacocinética de antivirales

Directorio
Miembros del grupo Infección por el VIH y farmacocinética de antivirales
  • Bachiller Sánchez Arévalo, Sara.Lda. Bioquímica. Doctora en Neurociencias
  • Domínguez Macías, Monserrat.Licenciado en Farmacia
  • Espinosa Aguilera, Nuria.Doctora en Medicina y Cirugía. FEA HUVR
  • Gasca Capote, Mª del Carmen.Investigadora Predoctoral. Lda. en Bioquímica
  • Gutiérrez Valencia, Alicia.Doctora en Farmacia. Posdoctoral.
  • Herrera Hidalgo, Laura.Lda. en Farmacia. Técnico.
  • Herrero Romero, Marta.Lda. Medicina y Cirugía
  • Jiménez León, Mª Reyes.Investigadora Predoctoral . Lda. en Bioquímica
  • Llaves Flores, Silvia.Doctora en Documentación
  • López Cortés, Luis Fernando.Doctor en Medicina. FEA/Profesor Asociado (HUVR/Univ. de Sevilla).
  • Milanés Guisado, Yusnelkis.Dra. Documentación
  • Muñoz Muela, Esperanza.Investigadora Predoctoral. Lda. en Farmacia
  • Neukam, Karin.Investigadora Miguel Servet I. Doctor en Farmacia
  • Ostos Marcos, Francisco José.Doctor en Ciencias Químicas
  • Rafii-el-Idrissi Benhnia, Mohammed.Doctor en Biología. Profesor Contratado Doctor de la US.
  • Rivas Jeremías, Inmaculada.Lda. en Farmacia. Técnico.
  • Ruiz-Mateos Carmona, Ezequiel.Co-IR Laboratorio Inmunovirología. Dr. Bioquímica Investigador estabilizado por el Programa Miguel Servet (tipo II). UGC de Enfermedades Infecciosas, Microbiología y Medicina Preventiva.
  • Saborido Alconchel, Abraham.Ldo. Biotecnología
  • Serna Gallego, Ana.Lda. Farmacia. Doctora en Biología
  • Sotomayor de la Piedra, César.Licenciado en Medicina. Máster universitario
  • Trujillo Rodríguez , María.Lda. Bioquímica. Predoctoral.
  • Viciana Fernández, Pompeyo Eduardo.Doctor en Medicina y Cirugía. Jefe de Sección (HUVR).
  • Vitalle Andrade, Joana.Lda. Biología. Doctora en Biología Molecular

Áreas de trabajo

Farmacocinética de antivirales.

En esta línea de investigación se llevan a cabo estudios farmacocinéticos, farmacodinámicos y de interacciones, tanto en plasma como a nivel intracelular, en humanos y en modelos experimentales, de fármacos antivirales relacionados con la infección por el VIH, el virus C de la hepatitis y citomegalovirus. Se le presta particular atención a aquellos estudios con aplicación clínica inmediata como la reducción de dosificaciones de algunos fármacos frente al VIH o el VHC, guiada por las concentraciones plasmáticas de éstos o el análisis de distintas pautas de dosificación para evitar sus efectos adversos.

Asimismo, se llevan a cabo programas de monitorización terapéutica de antirretrovirales en situaciones especiales como la gestación o la cirrosis hepática. Varios de estos proyectos se han realizado en colaboración con otros hospitales del Servicio Andaluz de Salud, en el ámbito de la Sociedad Andaluza de Enfermedades Infecciosas. En los últimos años, varios de estos estudios se han llevado a cabo y otros están en activo como ensayos clínicos promovidos por los propios investigadores, sin relación con la industria farmacéutica.

Revistas Internacionales
Dominguez-Molina, B; Tarancon-Diez, L; Milanes-Guisado, Y; Genebat, M; Resino, S; Rodriguez, C; Gonzalez-Garcia, J; Rallon, N; Pernas, M; Casado, C; Lopez-Galindez, C; Leon, A; Benito, JM; Garcia, F; Del Romero, J; Viciana, P; Lopez-Cortes, LF; Leal, M; Ruiz-Mateos, E
Persistent HIV-controllers are more prone to spontaneously clear HCV: a retrospective cohort study
JOURNAL OF THE INTERNATIONAL AIDS SOCIETY
Trujillo-Rodriguez, M; Viciana, P; Rivas-Jeremias, I; Alvarez-Rios, AI; Ruiz-Garcia, A; Espinosa-Ibanez, O; Arias-Santiago, S; Martinez-Atienza, J; Mata, R; Fernandez-Lopez, O; Ruiz-Mateos, E; Gutierrez-Valencia, A; Lopez-Cortes, LF
Mesenchymal stromal cells in Human Immunodeficiency Virus-infected patients with discordant immune response: Early results of a phase I/II clinical trial
STEM CELLS TRANSLATIONAL MEDICINE
Lujan-Valencia, JE; Lopez-Cortes, LE; Calvo-Jambrina, R; Barquero-Aroca, JM; Galvez-Acebal, J
Sequential antimicrobial therapy in mediastinitis after cardiac surgery: An observational study of 81 cases
ENFERMEDADES INFECCIOSAS Y MICROBIOLOGIA CLINICA
Mazzotta, S; Marrugal-Lorenzo, JA; Vega-Holm, M; Serna-Gallego, A; Alvarez-Vidal, J; Berastegui-Cabrera, J; del Palacio, JP; Diaz, C; Aiello, F; Pachon, J; Iglesias-Guerra, F; Vega-Perez, JM; Sanchez-Cespedes, J
Optimization of piperazine-derived ureas privileged structures for effective antiadenovirus agents
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
Herrera-Hidalgo, L; Gil-Navarro, MV; Penchala, SD; Lopez-Cortes, LE; de Alarcon, A; Luque-Marquez, R; Lopez-Cortes, LF; Gutierrez-Valencia, A
Ceftriaxone pharmacokinetics by a sensitive and simple LC-MS/MS method: Development and application
JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS
Abdo-Cuza, AA; Gomez-Bravo, MA; Perez-Bernal, JB; Suarez-Lopez, J; Gomez-Peire, F; Leiva-Torres, JL; Bejerano-Gil, N; Leal-Alpizar, G; Espinosa-Nodarse, N; Castellanos-Gutierrez, R
Health Care-Associated Infection in Solid Organ Transplant Recipients
TRANSPLANTATION PROCEEDINGS
Kuehl, R; Morata, L; Boeing, C; Subirana, I; Seifert, H; Rieg, S; Kern, WV; Kim, HB; Kim, ES; Liao, CH; Tilley, R; Lopez-Cortes, LE; Llewelyn, MJ; Fowler, VG; Thwaites, G; Cisneros, JM; Scarborough, M; Nsutebu, E; Ferrer, MG; Perez, JL; Barlow, G; Hopkins, S; Ternavasio-de La Vega, HG; Torok, ME; Wilson, P; Kaasch, AJ; Soriano, A
Defining persistent Staphylococcus aureus bacteraemia: secondary analysis of a prospective cohort study
LANCET INFECTIOUS DISEASES
Kared, H; Tan, SW; Lau, MC; Chevrier, M; Tan, C; How, W; Wong, G; Strickland, M; Malleret, B; Amoah, A; Pilipow, K; Zanon, V; Mc Govern, N; Lum, J; Chen, JM; Lee, B; Florian, MC; Geiger, H; Ginhoux, F; Ruiz-Mateos, E; Fulop, T; Rajasuriar, R; Kamarulzaman, A; Ng, TP; Lugli, E; Larbi, A
Immunological history governs human stem cell memory CD4 heterogeneity via the Wnt signaling pathway
NATURE COMMUNICATIONS
Casado, C; Galvez, C; Pernas, M; Tarancon-Diez, L; Rodriguez, C; Sanchez-Merino, V; Vera, M; Olivares, I; De Pablo-Bernal, R; Merino-Mansilla, A; Del Romero, J; Lorenzo-Redondo, R; Ruiz-Mateos, E; Salgado, M; Martinez-Picado, J; Lopez-Galindez, C
Permanent control of HIV-1 pathogenesis in exceptional elite controllers: a model of spontaneous cure
SCIENTIFIC REPORTS
Vitalle, J; Terren, I; Gamboa-Urquijo, L; Orrantia, A; Tarancon-Diez, L; Genebat, M; Leal, M; Ruiz-Mateos, E; Borrego, F; Zenarruzabeitia, O
Polyfunctional HIV-1 specific response by CD8+T lymphocytes expressing high levels of CD300a
SCIENTIFIC REPORTS
Vizcarra, P; Blanco, JL; Montejano, R; Negredo, E; Espinosa, N; Casado, JL; Monsalvo, M; Blanco, JL; Bernardino, JI; Puig, J; Montero, M; Castro, I; Mena, A; Castro, A; Palacios, R; de Quiros, JCLB; Tejerina, F; Latorre, LP; Ramirez, M; Vergas, J; Tellez, MJ; Galindo, P; Vilalta, RF; Cabello, A; Deltoro, MG; Cuevas, PR; de Santiago, AD; Moral, SD
Lack of impact of protease inhibitor resistance-associated mutations on the outcome of HIV-1-infected patients switching to darunavir-based dual therapy
INFECTIOUS DISEASES
Guerrero-Beltran, C; Martinez-Sanz, J; Alvarez, M; Olalla, J; Garcia-Alvarez, M; Iribarren, JA; Masia, M; Montero, M; Garcia-Bujalance, S; Blanco, JR; Rivero, M; Garcia-Fraile, LJ; Espinosa, N; Rodriguez, C; Aguilera, A; Vidal-Ampurdanes, MC; Martinez, M; Iborra, A; Imaz, A; Gomez-Sirvent, JL; Peraire, J; Portilla, J; Caballero, E; Alejos, B; Garcia, F; Moreno, S
The algorithm used for the interpretation of doravirine transmitted drug resistance strongly influences clinical practice and guideline recommendations
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
Milanes-Guisado, Y; Gutierrez-Valencia, A; Munoz-Pichardo, JM; Rivero, A; Trujillo-Rodriguez, M; Ruiz-Mateos, E; Espinosa, N; Roca-Oporto, C; Viciana, P; Lopez-Cortes, LF
Is immune recovery different depending on the use of integrase strand transfer inhibitor-, non-nucleoside reverse transcriptase- or boosted protease inhibitor-based regimens in antiretroviral-naive HIV-infected patients?
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
Cardozo, C; Cuervo, G; Salavert, M; Merino, P; Gioia, F; Fernandez-Ruiz, M; Lopez-Cortes, LE; Escola-Verge, L; Montejo, M; Munoz, P; Aguilar-Guisado, M; Puerta-Alcalde, P; Tasias, M; Ruiz-Gaitan, A; Gonzalez, F; Puig-Asensio, M; Vena, A; Marco, F; Peman, J; Fortun, J; Aguado, JM; Almirante, B; Soriano, A; Carratala, J; Garcia-Vidal, C
An evidence-based bundle improves the quality of care and outcomes of patients with candidaemia
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
Grillo, S; Cuervo, G; Carratala, J; Grau, I; Llaberia, M; Aguado, JM; Lopez-Cortes, LE; Lalueza, A; Sanjuan, R; Sanchez-Batanero, A; Ardanuy, C; Garcia-Somoza, D; Tebe, C; Pujol, M
Characteristics and Outcomes of Staphylococcus aureus Bloodstream Infection Originating From the Urinary Tract: A Multicenter Cohort Study
OPEN FORUM INFECTIOUS DISEASES
Vitalle, J; Tarancon-Diez, L; Jimenez-Leon, MR; Terren, I; Orrantia, A; Roca-Oporto, C; Lopez-Cortes, L; Ruiz-Mateos, E; Zenarruzabeitia, O; Borrego, F
CD300a identifies a CD4(+)memory T cell subset with a higher susceptibility to HIV-1 infection
AIDS
Herrera-Hidalgo, L; Lopez-Cortes, LE; Luque-Marquez, R; Galvez-Acebal, J; de Alaron, A; Lopez-Cortes, LF; Gutierrez-Valencia, A; Gil-Navarro, MV
Ampicillin and Ceftriaxone Solution Stability at Different Temperatures in Outpatient Parenteral Antimicrobial Therapy
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
De Pablo-Bernal, RS; Jimenez-Leon, MR; Tarancon-Diez, L; Gutierrez-Valencia, A; Serna-Gallego, A; Trujillo-Rodriguez, M; Alvarez-Rios, AI; Milanes-Guisado, Y; Espinosa, N; Roca-Oporto, C; Viciana, P; Lopez-Cortes, LF; Ruiz-Mateos, E
Modulation of Monocyte Activation and Function during Direct Antiviral Agent Treatment in Patients Coinfected with HIV and Hepatitis C Virus
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
Zuniga, MAL; Chueca, N; de Salazar, A; Caballero, JAF; Valencia, AG; Garcia, DV; Balgahata, MOM; Tenorio, CH; Lopez-Ruz, MA; Garcia, F
Genetic diversity of HIV in seminal plasma remains higher than in blood after short-term antiretroviral therapy
SEXUALLY TRANSMITTED INFECTIONS
Pothlichet, J; Rose, T; Bugault, F; Jeammet, L; Meola, A; Haouz, A; Saul, F; Geny, D; Alcami, J; Ruiz-Mateos, E; Teyton, L; Lambeau, G; Theze, J
PLA2G1B is involved in CD4 anergy and CD4 lymphopenia in HIV-infected patients
JOURNAL OF CLINICAL INVESTIGATION
Casado, JL; Vizcarra, P; Blanco, JL; Montejano, R; Negredo, E; Espinosa, N; Montero, M; Mena, A; Palacios, R; Lopez, JC; Vergas, J; Galindo, MJ; Cabello, A; Deltoro, MG; De Santiago, AD
Maintenance of virologic suppression and improvement in comorbidities after simplification to raltegravir plus boosted darunavir among treatment-experienced HIV-infected patients
INTERNATIONAL JOURNAL OF STD & AIDS
Hidalgo-Tenorio, C; Galvez, J; Martinez-Marcos, FJ; Plata-Ciezar, A; De La Torre-Lima, J; Lopez-Cortes, LE; Noureddine, M; Reguera, JM; Vinuesa, D; Garcia, MV; Ojeda, G; Luque, R; Lomas, JM; Lepe, JA; de Alarcon, A
Clinical and prognostic differences between methicillin-resistant and methicillin-susceptible Staphylococcus aureus infective endocarditis
BMC INFECTIOUS DISEASES
Suarez-Garcia, I; Moreno, C; Ruiz-Alguero, M; Perez-Elias, MJ; Navarro, M; Martinez, MD; Viciana, P; Perez-Martinez, L; Gorgolas, M; Amador, C; de Zarraga, MA; Jarrin, I
Effectiveness of the combination elvitegravir/cobicistat/tenofovir/emtricitabine (EVG/COB/TFV/FTC) plus darunavir among treatment-experienced patients in clinical practice: a multicentre cohort study
AIDS RESEARCH AND THERAPY
Bassetti, M; Vena, A; Meroi, M; Cardozo, C; Cuervo, G; Giacobbe, DR; Salavert, M; Merino, P; Gioia, F; Fernandez-Ruiz, M; Lopez-Cortes, LE; Almirante, B; Escola-Verge, L; Montejo, M; Aguilar-Guisado, M; Puerta-Alcalde, P; Tasias, M; Ruiz-Gaitan, A; Gonzalez, F; Puig-Asensio, M; Marco, F; Peman, J; Fortun, J; Aguado, JM; Soriano, A; Carratala, J; Garcia-Vidal, C; Valerio, M; Sartor, A; Bouza, E; Munoz, P
Factors associated with the development of septic shock in patients with candidemia: a post hoc analysis from two prospective cohorts
CRITICAL CARE
Herrera-Hidalgo, L; de Alarcon, A; Lopez-Cortes, LE; Luque-Marquez, R; Lopez-Cortes, LF; Gutierrez-Valencia, A; Gil-Navarro, MV
Enterococcus faecalis Endocarditis and Outpatient Treatment: A Systematic Review of Current Alternatives
ANTIBIOTICS-BASEL
Gil-Navarro, MV; Luque-Marquez, R; Baez-Gutierrez, N; Alvarez-Marin, R; Navarro-Amuedo, MD; Praena-Segovia, J; Carmona-Caballero, JM; Fraile-Ramos, E; Lopez-Cortes, LE
Antifungal treatment administered in OPAT programs is a safe and effective option in selected patients
ENFERMEDADES INFECCIOSAS Y MICROBIOLOGIA CLINICA
Lopez-Cortes, LE; Galvez-Acebal, J; Rodriguez-Bano, J
Therapy of Staphylococcus aureus bacteremia: Evidences and challenges
ENFERMEDADES INFECCIOSAS Y MICROBIOLOGIA CLINICA
RODGER AJ, CAMBIANO V, BRUUN T, VERNAZZA P, COLLINS S, DEGEN O, CORBELLI GM, ESTRADA V, GERETTI AM, BELOUKAS A, RABEN D, COLL P, ANTINORI A, NWOKOLO N, RIEGER A, PRINS JM, BLAXHULT A, WEBER R, VAN EEDEN A, BROCKMEYER NH, CLARKE A, DEL ROMERO GUERRERO J, RAFFI F, BOGNER JR, WANDELER G, GERSTOFT J, GUTIERREZ F, BRINKMAN K, KITCHEN M, OSTERGAARD L, LEON A, RISTOLA M, JESSEN H, STELLBRINK HJ, PHILLIPS AN, LUNDGREN J, PARTNER STUDY GROUP
RISK OF HIV TRANSMISSION THROUGH CONDOMLESS SEX IN SERODIFFERENT GAY COUPLES WITH THE HIV-POSITIVE PARTNER TAKING SUPPRESSIVE ANTIRETROVIRAL THERAPY (PARTNER): FINAL RESULTS OF A MULTICENTRE, PROSPECTIVE, OBSERVATIONAL STUDY.
LANCET.
PEREZ AB, CHUECA N, GARCIA-DELTORO M, MARTINEZ-SAPIÑA AM, LARA-PEREZ MM, GARCIA-BUJALANCE S, ALDAMIZ-ECHEVARRIA T, VERA-MENDEZ FJ, PINEDA JA, CASADO M, PASCASIO JM, SALMERON J, ALADOS-ARBOLEDAS JC, POYATO A, TELLEZ F, RIVERO-JUAREZ A, MERINO D, VIVANCOS-GALLEGO MJ, ROSALES-ZABAL JM, GARCIA F, GEHEP-004 STUDY GROUP
HIGH EFFICACY OF RESISTANCE-GUIDED RETREATMENT OF HCV PATIENTS FAILING NS5A INHIBITORS IN THE REAL WORLD.
J HEPATOL.
VICIANA P, MILANES-GUISADO Y, FONTILLON M, DOMINGUEZ CASTAÑO A, SOTOMAYOR C, ESPINOSA N, LOPEZ-CORTES LF, NEUKAM K
HIGH-RISK HUMAN PAPILLOMA VIRUS TESTING IMPROVES DIAGNOSTIC PERFORMANCE TO PREDICT MODERATE- TO HIGH-GRADE ANAL INTRAEPITHELIAL NEOPLASIA IN HUMAN IMMUNODEFICIENCY VIRUS-INFECTED MEN WHO HAVE SEX WITH MEN IN LOW-TO-ABSENT CYTOLOGICAL ABNORMALITIES.
CLIN INFECT DIS
TARANCON-DIEZ L, RODRIGUEZ-GALLEGO E, RULL A, PERAIRE J, VILADES C, PORTILLA I, JIMENEZ-LEON MR, ALBA V, HERRERO P, LEAL M, RUIZ-MATEOS E, VIDAL F, ECRIS INTEGRATED IN THE SPANISH AIDS RESEARCH NETWORK
IMMUNOMETABOLISM IS A KEY FACTOR FOR THE PERSISTENT SPONTANEOUS ELITE CONTROL OF HIV-1 INFECTION.
EBIOMEDICINE.
JIMENEZ-SOUSA MA, JIMENEZ JL, FERNANDEZ-RODRIGUEZ A, BROCHADO-KITH O, BELLON JM, GUTIERREZ F, DIEZ C, BERNAL-MORELL E, VICIANA P, MUÑOZ-FERNANDEZ MA, RESINO S
VDR RS2228570 POLYMORPHISM IS RELATED TO NON-PROGRESSION TO AIDS IN ANTIRETROVIRAL THERAPY NAÏVE HIV-INFECTED PATIENTS.
J CLIN MED.
BRISTOW CL, FERRANDO-MARTINEZ S, RUIZ-MATEOS E, LEAL M, WINSTON R
T CELLS REQUIRES ALPHA-1 ANTITRYPSIN AS OBSERVED BY TREATMENT IN HIV-1 INFECTED AND UNINFECTED CONTROLS.
FRONT CELL DEV BIOL.
ALVAREZ M, CASAS P, DE SALAZAR A, CHUECA N, GUERRERO-BELTRAN C, RODRIGUEZ C, IMAZ A, ESPINOSA N, GARCIA-BUJALANCE S, PEREZ-ELIAS MJ, GARCIA-ALVAREZ M, IRIBARREN JA, SANTOS J, DALMAU D, AGUILERA A, VINUESA D, GUTIERREZ F, PIEROLA B, MOLINA JM, PERAIRE J, PORTILLA I, GOMEZ-SIRVENT JL, OLALLA J, GALERA C, BLANCO JR, RIERA M, GARCIA-FRAILE L, NAVARRO G, CURRAN A, POVEDA E, GARCIA F, CORIS
SURVEILLANCE OF TRANSMITTED DRUG RESISTANCE TO INTEGRASE INHIBITORS IN SPAIN: IMPLICATIONS FOR CLINICAL PRACTICE.
J ANTIMICROB CHEMOTHER.
RODRIGUEZ-GALLEGO E, TARANCON-DIEZ L, GARCIA F, DEL ROMERO J, BENITO JM, ALBA V, HERRERO P, RULL A, DOMINGUEZ-MOLINA B, MARTINEZ-MADRID O, MARTIN-PENA L, PULIDO F, LEON A, RODRIGUEZ C, RALLON N, PERAIRE J, VILADES C, LEAL M, VIDAL F, RUIZ-MATEOS E, HIV-1 ELITE CONTROLLERS STUDY GROUP (ECRIS), SPANISH AIDS RESEARCH NETWORK
PROTEOMIC PROFILE ASSOCIATED WITH LOSS OF SPONTANEOUS HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 ELITE CONTROL.
J INFECT DIS.
RESINO S, NAVARRETE-MUÑOZ MA, BLANCO J, PACHECO YM, CASTRO I, BERENGUER J, SANTOS J, VERA-MENDEZ FJ, GORGOLAS M, JIMENEZ-SOUSA MAA, BENITO JM, RALLON N, CORIS AND THE HIV BIOBANK INTEGRATED IN THE SPANISH AIDS RESEARCH NETWORK PROJECT RIS/EPICLIN 10_2015
IL7RA RS6897932 POLYMORPHISM IS ASSOCIATED WITH BETTER CD4+ T-CELL RECOVERY IN HIV INFECTED PATIENTS STARTING COMBINATION ANTIRETROVIRAL THERAPY.
BIOMOLECULES.
KOSTAKI EG, FLAMPOURIS A, KARAMITROS T, CHUECA N, ALVAREZ M, CASAS P, ALEJOS B, HATZAKIS A, GARCIA F, PARASKEVIS D, CORIS
SPATIOTEMPORAL CHARACTERISTICS OF THE LARGEST HIV-1 CRF02_AG OUTBREAK IN SPAIN: EVIDENCE FOR ONWARD TRANSMISSIONS.
FRONT MICROBIOL.
GENEBAT M, TARANCON-DIEZ L, PULIDO I, ALVAREZ-RIOS AI, MUÑOZ-FERNANDEZ MA, RUIZ-MATEOS E, LEAL M
HEPATITIS C VIRUS AND CUMULATIVE INFECTIONS ARE ASSOCIATED WITH ATHEROGENIC CARDIOVASCULAR EVENTS IN HIV-INFECTED SUBJECTS.
ANTIVIRAL RES.
NEUKAM K, MILANES GUISADO Y, FONTILLON M, MERINO L, SOTOMAYOR C, ESPINOSA N, LOPEZ-CORTES LF, VICIANA P, SEVIHANAL STUDY GROUP
HIGH-RESOLUTION ANOSCOPY IN HIV-INFECTED MEN: ASSESSMENT OF THE LEARNING CURVE AND FACTORS THAT IMPROVE THE PERFORMANCE.
PAPILLOMAVIRUS RES.
CEAUSU A, RODRIGUEZ-GALLEGO E, PERAIRE J, LOPEZ-DUPLA M, DOMINGO P, VILADES C, VIDAL-GONZALEZ J, PERAIRE M, PERPIÑAN C, PACHECO YM, VELOSO S, ALBA V, VARGAS M, CASTELLANO AJ, RUIZ-MATEOS E, MALLOLAS J, VIDAL F, RULL A
IL-7/IL-7R GENE VARIANTS IMPACT CIRCULATING IL-7/IL-7R HOMEOSTASIS AND ART-ASSOCIATED IMMUNE RECOVERY STATUS.
SCI REP.
MARRUGAL-LORENZO JA, SERNA-GALLEGO A, BERASTEGUI-CABRERA J, PACHON J, SANCHEZ-CESPEDES J
REPOSITIONING SALICYLANILIDE ANTHELMINTIC DRUGS TO TREAT ADENOVIRUS INFECTIONS.
SCI REP.
NEUKAM K, DELGADO FERNANDEZ M, HERNANDEZ QUERO J, RIVERO-JUAREZ A, LLAVES-FLORES S, JIMENEZ OÑATE F, GUTIERREZ-VALENCIA A, ESPINOSA N, VICIANA P, LOPEZ-CORTES LF
BRIEF REPORT: RESPONSE TO HEPATITIS A VIRUS VACCINE IN HIV-INFECTED PATIENTS WITHIN A RETROSPECTIVE, MULTICENTRIC COHORT: FACING HEPATITIS A OUTBREAKS IN THE CLINICAL PRACTICE.
J ACQUIR IMMUNE DEFIC SYNDR.
RIVERO-JUAREZ A, TELLEZ F, CASTAÑO-CARRACEDO M, MERINO D, ESPINOSA N, SANTOS J, MACIAS J, PANIAGUA-GARCIA M, ZAPATA-LOPEZ A, COLLADO A, GOMEZ-VIDAL MA, PEREZ-STACHOWSKI J, MUÑOZ-MEDINA L, FERNANDEZ-FUERTES E, RIVERO A, GRUPO DE ESTUDIO DE HEPATITIS VIRALES (HEPAVIR) OF THE SOCIEDAD ANDALUZA DE ENFERMEDADES INFECCIOSAS (SAEI)
PARENTERAL DRUG USE AS THE MAIN BARRIER TO HEPATITIS C TREATMENT UPTAKE IN HIV-INFECTED PATIENTS.
HIV MED
NEUKAM K, GUTIERREZ-VALENCIA A, LLAVES-FLORES S, ESPINOSA N, VICIANA P, LOPEZ-CORTES LF
RESPONSE TO A REINFORCED HEPATITIS B VACCINATION SCHEME IN HIV-INFECTED PATIENTS UNDER REAL-LIFE CONDITIONS.
VACCINE.
GUTIERREZ-SABORIDO D, GUTIERREZ-VALENCIA A, GONZALEZ DOMENECH CM, LOPEZ RUZ MA, RAFFO MARQUEZ M, OMAR M, GIRON-GONZALEZ JA, GRUPO DE ESTUDIO DE HEPATITIS VIRALES (HEPAVIR) OF THE SOCIEDAD ANDALUZA DE ENFERMEDADES INFECCIOSAS (SAEI)
INCIDENCE OF LYMPHOMA IN HIV-HCV-INFECTED PATIENTS. MODIFICATIONS IN FUNCTION OF THE ANTI-HEPATITIS C VIRUS THERAPY.
ANN HEMATOL.
ALEJOS B, SUAREZ-GARCIA I, BISBAL O, IRIBARREN JA, ASENSI V, GORGOLAS M, MUGA R, MORENO S, JARRIN I, CORIS COHORT
CHOICE OF THE INITIAL ANTIRETROVIRAL TREATMENT FOR HIV-POSITIVE INDIVIDUALS IN THE ERA OF INTEGRASE INHIBITORS.
PLOS ONE
MANUEL SOUSA J, VERGARA M, PULIDO F, SANCHEZ ANTOLIN G, HIJONA L, CARNICER F, RINCON D, SALMERON J, MATEOS-MUÑOZ B, JOU A, POLO-LORDUY B, RUBIN A, ESCARDA A, AGUILAR P, ALDAMIZ-ECHEVARRIA T, GARCIA-BUEY L, CARRION JA, HERNANDEZ-GUERRA M, CHIMENO-HERNANDEZ S, ESPINOSA N, MORILLAS RM, ANDRADE RJ, DELGADO M, GALLEGO A, MAGAZ M, MORENO-PLANAS JM, ESTEBANEZ A, RICO M, MENENDEZ F, SAMPEDRO B, MORANO L, IZQUIERDO S, ZOZAYA JM, RODRIGUEZ M, MORAN-SANCHEZ S, LORENTE S, MARTIN-GRANIZO I, VON-WICHMANN MA, DELGADO M, MANZANARES A
REAL-WORLD EVIDENCE OF THE EFFECTIVENESS OF OMBITASVIR-PARITAPREVIR/R ± DASABUVIR ± RIBAVIRIN IN PATIENTS MONOINFECTED WITH CHRONIC HEPATITIS C OR COINFECTED WITH HUMAN IMMUNODEFICIENCY VIRUS-1 IN SPAIN.
PLOS ONE.
RAMIREZ DE ARELLANO E, DIEZ-FUERTES F, AGUILAR F, DE LA TORRE TARAZONA HE, SANCHEZ-LARA S, LAO Y, VICARIO JL, GARCIA F, GONZALEZ-GARCIA J, PULIDO F, GUTIERREZ-RODERO F, MORENO S, IRIBARREN JA, VICIANA P, VILCHES C, RAMOS M, CAPA L, ALCAMI J, DEL VAL M
NOVEL ASSOCIATION OF FIVE HLA ALLELES WITH HIV-1 PROGRESSION IN SPANISH LONG-TERM NON PROGRESSOR PATIENTS.
PLOS ONE.
RUIZ-MATEOS E, RUIZ-LEON MJ, TARANCON-DIEZ L, GUTIERREZ C, DRONDA F, DOMINGUEZ-MOLINA B, PEREZ-ELIAS MJ, MORENO A, LEAL M, MORENO S, VALLEJO A
HIGH CD8 T CELL PERCENTAGE AND HCV REPLICATION CONTROL ARE COMMON FEATURES IN HIV-1 CONTROLLERS AND HTLV-2-CO-INFECTED PATIENTS WITH A HISTORY OF INJECTION DRUG USE.
VIRUS RES.
RUIZ-DE-LEON MJ, JIMENEZ-SOUSA MA, MORENO S, GARCIA M, GUTIERREZ-RIVAS M, LEON A, MONTERO-ALONSO M, GONZALEZ-GARCIA J, RESINO S, RALLON N, BENITO JM, VALLEJO A, ECRIS NETWORK INTEGRATED IN THE SPANISH AIDS RESEARCH NETWORK
LOWER EXPRESSION OF PLASMA-DERIVED EXOSOME MIR-21 LEVELS IN HIV-1 ELITE CONTROLLERS WITH DECREASING CD4 T CELL COUNT.
J MICROBIOL IMMUNOL INFECT.
MARTINEZ AP, GARCIA G, RIDRUEJO E, CULASSO AC, PEREZ PS, PERESON MJ, NEUKAM K, FLICHMAN D, DI LELLO FA
HEPATITIS C VIRUS GENOTYPE 1 INFECTION: PREVALENCE OF NS5A AND NS5B RESISTANCE-ASSOCIATED SUBSTITUTIONS IN NAÏVE PATIENTS FROM ARGENTINA.
J MED VIROL.
HIDALGO-TENORIO C, CORTES LL, GUTIERREZ A, SANTOS J, OMAR M, GALVEZ C, SEQUERA S, JESUS SE, TELLEZ F, FERNANDEZ E, GARCIA C, PASQUAU J
DOLAMA STUDY: EFFECTIVENESS, SAFETY AND PHARMACOECONOMIC ANALYSIS OF DUAL THERAPY WITH DOLUTEGRAVIR AND LAMIVUDINE IN VIROLOGICALLY SUPPRESSED HIV-1 PATIENTS.
MEDICINE (BALTIMORE).
AIDS STUDY GROUP (GESIDA) OF THE SPANISH SOCIETY OF INFECTIOUS DISEASES AND CLINICAL MICROBIOLOGY
EXECUTIVE SUMMARY OF THE GESIDA CONSENSUS DOCUMENT ON CONTROL AND MONITORING OF HIV-INFECTED PATIENTS.
ENFERM INFECC MICROBIOL CLIN.
AIDS STUDY GROUP (GESIDA) OF THE SPANISH SOCIETY OF INFECTIOUS DISEASES AND CLINICAL MICROBIOLOGY AND THE NATIONAL AIDS PLAN:
EXECUTIVE SUMMARY OF THE GESIDA/NATIONAL AIDS PLAN CONSENSUS DOCUMENT ON ANTIRETROVIRAL THERAPY IN ADULTS INFECTED BY THE HUMAN IMMUNODEFICIENCY VIRUS (UPDATED JANUARY 2018).
ENFERM INFECC MICROBIOL CLIN.
SUAREZ-GARCIA I, GONZALEZ J, BERENGUER J, GARCIA F, PORTILLA J, MUGA R, MORENO S, JARRIN I, COHORT OF THE SPANISH HIV RESEARCH NETWORK (CORIS)
REASONS FOR NONCOMPLIANCE WITH THE NATIONAL GUIDELINES FOR INITIAL ANTIRETROVIRAL THERAPY OF HIV-INFECTED PATIENTS IN SPAIN, 2010-2015.
ENFERM INFECC MICROBIOL CLIN.
TEIRA R, ESPINOSA N, GUTIERREZ MM, MONTERO M, MARTINEZ E, GONZALEZ F, LOZANO DE LEON F, TELLEZ F, GALINDO MJ, PERAIRE J, DEIG E, MUÑOZ-SANCHEZ P, PARA EL GRUPO DE ESTUDIO VACH
LOSSES TO FOLLOW-UP OF HIV-INFECTED PEOPLE IN THE SPANISH VACH COHORT OVER THE PERIOD BETWEEN 2013 AND 2014: THE IMPORTANCE OF SOCIODEMOGRAPHIC FACTORS.
ENFERM INFECC MICROBIOL CLIN.
GUISADO-GIL AB, HERRERA-HIDALGO L, SANTOS-RUBIO MD, GIL-SACALUGA L, MOLINA J, LEPE-JIMENEZ JA, CAMACHO-MARTINEZ P, GIL-NAVARRO MV
GENTAMICIN AS EMPIRICAL TREATMENT IN HEMODIALYSIS PATIENTS: SAFETY, PHARMACOKINETICS, AND PHARMACODYNAMICS.
THER APHER DIAL.
AIDS Study Group (GESIDA), National Aids Plan null, STI Study group of the SEIMC (GEITS), Spanish Group for the Investigation of Sexual Transmission Diseases of the Spanish Academy of Dermatology and Venerology, Spanish Society for Pediatric Infectious (SEIP).
Consensus document on the diagnosis and treatment of sexually transmitted diseases in adults, children and adolescents.
Enferm Infecc Microbiol Clin.
Álvarez-Ossorio MJ, Sarmento E Castro R, Granados R, Macías J, Morano-Amado LE, Ríos MJ, Merino D, Álvarez EN, Collado A, Pérez-Pérez M, Téllez F, Martín JM, Méndez J, Pineda JA, Neukam K, HEPAVIR-DAA, GEHEP-MONO, RIS-HEP07 and RIS-HEP13 Study Groups.
Impact of interferon-free regimens on the glomerular filtration rate during treatment of chronic hepatitis C in a real-life cohort.
J Viral Hepat.
Benito JM, Hillung J, Restrepo C, Cuevas JM, León A, Ruiz-Mateos E, Palacios-Muñoz R, Górgolas M, Sanjuán R, Rallón N.
Role of APOBEC3H in the Viral Control of HIV Elite Controller Patients.
International journal of medical sciences
Benito JM, Ortiz MC, León A, Sarabia LA, Ligos JM, Montoya M, García M, Ruiz-Mateos E, Palacios R, Cabello A, Restrepo C, Rodríguez C, Del Romero J, Leal M, Muñoz-Fernández MA, Alcamí J, García F, Górgolas M, Rallón N, ECRIS integrated in the Spanish AIDS Research Network.
Class-modeling analysis reveals T-cell homeostasis disturbances involved in loss of immune control in elite controllers.
BMC Med.
Domínguez-Molina B, Ferrando-Martínez S, Tarancón-Díez L, Hernández-Quero J, Genebat M, Vidal F, Muñoz-Fernández MA, Leal M, Koup R, Ruiz-Mateos E
Immune Correlates of Natural HIV Elite Control and Simultaneous HCV Clearance-Supercontrollers.
Front Immunol.
Domínguez-Molina B, Machmach K, Perales C, Tarancón-Díez L, Gallego I, Sheldon JL, Leal M, Domingo E, Ruiz-Mateos E.
Toll-Like Receptor 7 (TLR-7) and TLR-9 Agonists Improve Hepatitis C Virus Replication and Infectivity Inhibition by Plasmacytoid Dendritic Cells.
J Virol.
Gutiérrez-Valencia A, García C, Viciana P, Milanés-Guisado Y, Fernández-Magdaleno T, Espinosa N, Pasquau J, López-Cortés LF.
No difference in effectiveness of treatment simplification to boosted or unboosted atazanavir plus lamivudine in virologically suppressed in HIV-1-infected patients.
PLoS One.
Gutiérrez-Valencia A, Trujillo-Rodríguez M, Fernández-Magdaleno T, Espinosa N, Viciana P, López-Cortés LF
Darunavir/cobicistat showing similar effectiveness as darunavir/ritonavir monotherapy despite lower trough concentrations.
J Int AIDS Soc.
Herrero-Fernández I, Rosado-Sánchez I, Genebat M, Tarancón-Díez L, Rodríguez-Méndez MM, Pozo-Balado MM, Lozano C, Ruiz-Mateos E, Leal M, Pacheco YM.
Improved CD4 T cell profile in HIV-infected subjects on maraviroc-containing therapy is associated with better responsiveness to HBV vaccination.
J Transl Med.
Hua S, Vigano S, Tse S, Zhengyu O, Harrington S, Negrón J, García-Broncano P, Marchetti G, Genebat M, Leal M, Resino S, Ruiz-Mateos E, Lichterfeld M, Yu XG.
Pegylated Interferon-α-Induced Natural Killer Cell Activation Is Associated With Human Immunodeficiency Virus-1 DNA Decline in Antiretroviral Therapy-Treated HIV-1/Hepatitis C Virus-Coinfected Patients.
Clin Infect Dis.
López-Cortés LF, Trujillo-Rodríguez M, Báez-Palomo A, Benmarzouk-Hidalgo OJ, Domínguez-Molina B, Milanés-Guisado Y, Espinosa N, Viciana P, Gutiérrez-Valencia A.
Eradication of Hepatitis C Virus (HCV) Reduces Immune Activation, Microbial Translocation, and the HIV DNA Level in HIV/HCV-Coinfected Patients.
J Infect Dis.
. Milanés-Guisado Y, Gutiérrez-Valencia A, Trujillo-Rodríguez M, Espinosa N, Viciana P, López-Cortés LF.
Absolute CD4+ T cell count overstate immune recovery assessed by CD4+/CD8+ ratio in HIV-infected patients on treatment.
PLoS One.
Molina JM, Ward D, Brar I, Mills A, Stellbrink HJ, López-Cortés L, Ruane P, Podzamczer D, Brinson C, Custodio J, Liu H, Andreatta K, Martin H, Cheng A, Quirk E.
Switching to fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide from dolutegravir plus abacavir and lamivudine in virologically suppressed adults with HIV-1: 48-week results of a randomised, double-blind, multicentre, active-controlled, phase 3, non-inferiority trial.
Lancet HIV.
Neukam K, Ridruejo E, Pérez P, Campos RH, Martínez AP, Di Lello FA.
Prevalence of hepatitis C virus infection according to the year of birth: identification of risk groups.
Eur J Clin Microbiol Infect Dis.
Pernas M, Tarancón-Díez L, Rodríguez-Gallego E, Gómez J, Prado JG, Casado C, Domínguez-Molina B, Olivares I, Coiras M, León A, Rodríguez C, Benito JM, Rallón N, Plana M, Martínez-Madrid O, Dapena M, Iribarren JA, Del Romero J, García F, Alcamí J, Muñoz-Fernández M, Vidal F, Leal M, López-Galíndez C, Ruiz-Mateos E.
Factors Leading to the Loss of Natural Elite Control of HIV-1 Infection.
J Virol.
Rodríguez-Gallego E, Gómez J, Domingo P, Ferrando-Martínez S, Peraire J, Viladés C, Veloso S, López-Dupla M, Beltrán-Debón R, Alba V, Vargas M, Castellano AJ, Leal M, Pacheco YM, Ruiz-Mateos E, Gutiérrez F, Vidal F, Rull A, CORIS-NADES events Study Group.
Circulating metabolomic profile can predict dyslipidemia in HIV patients undergoing antiretroviral therapy.
Atherosclerosis.
Rosado-Sánchez I, Herrero-Fernández I, Tarancón-Díez L, Moreno S, Iribarren JA, Dalmau D, Vera-Méndez F, Leal M, Pacheco YM.
Increased frequencies of Th17 cells and IL17a-producing regulatory T-cells preceding the immunodiscordant response to antiretroviral treatment.
J Infect.
Ruiz-Mateos E, Tarancón-Díez L, Álvarez-Ríos AI, Domínguez-Molina B, Genebat M, Pulido I, Abad MA, Muñoz-Fernández MA, Leal M.
Association of heterozygous CCR5Δ32 deletion with survival in HIV-infection: A cohort study.
Antiviral Res.
Salgado M, García-Minambres A, Dalmau J, Jiménez-Moyano E, Viciana P, Alejos B, Clotet B, Prado JG, Martínez-Picado J.
Control of HIV-1 Pathogenesis in Viremic Nonprogressors Is Independent of Gag-Specific Cytotoxic T Lymphocyte Responses.
J Virol.
Tarancón-Díez L, De Pablo-Bernal RS, Jiménez JL, Álvarez-Ríos AI, Genebat M, Rosado-Sánchez I, Muñoz-Fernández MÁ, Ruiz-Mateos E, Leal M.
Role of toll-like receptor 4 Asp299Gly polymorphism in the development of cardiovascular diseases in HIV-infected patients
AIDS.
Tarancón-Díez L, Domínguez-Molina B, Viciana P, López-Cortés L, Ruiz-Mateos E.
Long-term Persistent Elite HIV-controllers: The Right Model of Functional Cure.
EBioMedicine
Teira R, Espinosa N, Gutiérrez MM, Montero M, Martínez E, González F, Lozano de León F, Téllez F, Galindo MJ, Peraire J, Deig E, Muñoz-Sánchez P, para el Grupo de estudio VACH.
Losses to follow-up of HIV-infected people in the Spanish VACH cohort over the period between 2013 and 2014: The importance of sociodemographic factors.
Enferm Infecc Microbiol Clin.
Vitallé J, Terrén I, Gamboa-Urquijo L, Orrantia A, Tarancón-Díez L, Genebat M, Ruiz-Mateos E, Leal M, García-Obregón S, Zenarruzabeitia O, Borrego F.
Altered Expression of CD300a Inhibitory Receptor on CD4+ T Cells From Human Immunodeficiency Virus-1-Infected Patients: Association With Disease Progression Markers.
Front Immunol.
Benmarzouk-Hidalgo OJ, Torres-Cornejo A, Gutiérrez-Valencia A, Viciana P, López-Cortés LF.
HIV-1 p24 and CD4(+)T cell count during boosted protease-inhibitor monotherapy in HIV-infected patients.
Enferm Infecc Microbiol Clin.
. Domínguez-Molina B, Tarancón-Díez L, Hua S, Abad-Molina C, Rodríguez-Gallego E, Machmach K, Vidal F, Tural C, Moreno S, Goñi JM, Ramírez de Arellano E, Del Val M, González-Escribano MF, Del Romero J, Rodriguez C, Capa L, Viciana P, Alcamí J, Yu XG, Walker BD, Leal M, Lichterfeld M, Ruiz-Mateos E, ECRIS integrated in the Spanish AIDS Research Network.
HLA-B*57 and IFNL4-related polymorphisms are associated with protection against HIV-1 disease progression in controllers
Clin Infect Dis.
Ferrando-Martínez S, De Pablo-Bernal RS, De Luna-Romero M, De Ory SJ, Genebat M, Pacheco YM, Parras FJ, Montero M, Blanco JR, Gutiérrez F, Santos J, Vidal F, Koup RA, Muñoz-Fernández MÁ, Leal M, Ruiz-Mateos E.
Thymic Function Failure Is Associated With Human Immunodeficiency Virus Disease Progression.
Clin Infect Dis.
González-Serna A, Ferrando-Martínez S, Tarancón-Diez L, De Pablo-Bernal RS, Domínguez-Molina B, Jiménez JL, Muñoz-Fernández MÁ, Leal M, Ruiz-Mateos E.
Increased CD127+ and decreased CD57+ T cell expression levels in HIV-infected patients on NRTI-sparing regimens
J Transl Med.
Gutiérrez-Valencia A, Benmarzouk-Hidalgo OJ, Llaves S, Fernández-Magdaleno T, Espinosa N, Viciana P, López-Cortés LF.
Pharmacokinetic interactions between cobicistat-boosted elvitegravir and darunavir in HIV-infected patients.
J Antimicrob Chemother.
Gutiérrez-Valencia A, Benmarzouk-Hidalgo OJ, Rivas-Jeremías I, Espinosa N, Trujillo-Rodríguez M, Fernández-Magdaleno T, Viciana P, López-Cortés LF.
Viral Kinetics in Semen With Different Antiretroviral Families in Treatment-Naive Human Immunodeficiency Virus-Infected Patients: A Randomized Trial.
Clin Infect Dis.
. Martínez-Bonet M, González-Serna A, Clemente MI, Morón-López S, Díaz L, Navarro M, Puertas MC, Leal M, Ruiz-Mateos E, Martínez-Picado J, Muñoz-Fernández MA.
Relationship between CCR5(WT/Δ32) heterozygosity and HIV-1 reservoir size in adolescents and young adults with perinatally acquired HIV-1 infection
Clin Microbiol Infect.
Masiá M, Padilla S, Moreno S, Barber X, Iribarren JA, Del Romero J, Gómez-Sirvent JL, Rivero M, Vidal F, Campins AA, Gutiérrez F, Cohorte de la Red de Investigación en Sida (CoRIS).
Prediction of long-term outcomes of HIV-infected patients developing non-AIDS events using a multistate approach.
PLoS One.
Neukam K, Morano-Amado LE, Rivero-Juárez A, Mancebo M, Granados R, Téllez F, Collado A, Ríos MJ, de Los Santos-Gil I, Reus-Bañuls S, Vera-Méndez F, Geijo-Martínez P, Montero-Alonso M, Suárez-Santamaría M, Pineda JA.
HIV-coinfected patients respond worse to direct-acting antiviral-based therapy against chronic hepatitis C in real life than HCV-monoinfected individuals: a prospective cohort study.
HIV Clin Trials.
Pernas M, Tarancón-Díez L, Rodríguez-Gallego E, Gómez J, Prado JG, Casado C, Domínguez-Molina B, Olivares I, Coiras M, León A, Rodríguez C, Benito JM, Rallón N, Plana M, Martínez-Madrid O, Dapena M, Iribarren JA, Del Romero J, García F, Alcamí J, Muñoz-Fernández MÁ, Vidal F, Leal M, López-Galíndez C, Ruiz-Mateos E, ECRIS integrated in the Spanish AIDS Research Network.
Factors Leading to the Loss of Natural Elite Control of HIV-1 Infection.
J Virol.
Rivero-Juárez A, Lopez-Cortes LF, Castaño M, Merino D, Marquez M, Mancebo M, Cuenca-Lopez F, Jimenez-Aguilar P, Lopez-Montesinos I, Lopez-Cardenas S, Collado A, Lopez-Ruz MA, Omar M, Tellez F, Perez-Stachowski X, Hernandez-Quero J, Girón-Gonzalez JA, Fernandez-Fuertes E, Rivero A, HERACLES cohort study team of the Grupo de Estudio de Hepatitis Virales (HEPAVIR) of the Sociedad Andaluza de Enfermedades Infecciosas (SAEI).
Impact of universal access to hepatitis C therapy on HIV-infected patients: implementation of the Spanish national hepatitis C strategy.
Eur J Clin Microbiol Infect Dis.
Rosado-Sánchez I, Herrero-Fernández I, Álvarez-Ríos AI, Genebat M, Abad-Carrillo MA, Ruiz-Mateos E, Pulido F, González-García J, Montero M, Bernal-Morell E, Vidal F, Leal M, Pacheco YM.
A Lower Baseline CD4/CD8 T-Cell Ratio Is Independently Associated with Immunodiscordant Response to Antiretroviral Therapy in HIV-Infected Subjects.
Antimicrob Agents Chemother.
Rosado-Sánchez I, Jarrín I, Pozo-Balado MM, de Pablo-Bernal RS, Herrero-Fernández I, Alvarez-Ríos AI, Rodríguez-Gallego E, Genebat M, Vera M, Berenguer J, Martín ML, Bernal E, Vidal F, Blanco J, Leal M, Pacheco YM.
Higher levels of IL-6, CD4 turnover and Treg frequency are already present before cART in HIV-infected subjects with later low CD4 recovery.
Antiviral Res.
Tarancón-Díez L, De Pablo-Bernal RS, Álvarez-Ríos AI, Rosado-Sánchez I, Domínguez-Molina B, Genebat M, Pacheco YM, Jiménez JL, Muñoz-Fernández MÁ, Ruiz-Mateos E, Leal M.
CCR5+ CD8 T-cell levels and monocyte activation precede the onset of acute coronary syndrome in HIV-infected patients on antiretroviral therapy.
Thromb Haemost.
Teira R, Vidal F, Muñoz-Sánchez P, Geijo P, Viciana P, Ribera E, Domingo P, Castaño M, Martínez E, Roca B, Puig T, Estrada V, Deig E, Galindo MJ, de la Fuente B, Lozano F, Montero M, Muñoz-Sanz A, Sánchez T, Terrón A, Romero-Palacios A, Lacalle JR, Garrido M, Suárez-Lozano I, VACH Study Group.
Very low level viraemia and risk of virological failure in treated HIV-1-infected patients
HIV Med.
Viciana P.
Rilpivirine: The Key for Long-term Success.
AIDS Rev
Chereau F, Madec Y, Sabin C, Obel N, Ruiz-Mateos E, Chrysos G, Fidler S, Lehmann C, Zangerle R, Wittkop L, Reiss P, Hamouda O, Estrada Pérez V, Leal M, Mocroft A, García De Olalla P, Ammassari A, D'Arminio Monforte A, Mussini C, Segura F, Castagna A, Cavassini M, Grabar S, Morlat P, De Wit S, Lambotte O, Meyer L, HIV Controllers Project Working Group for the Collaboration of Observational HIV Epidemiological Research Europe (COHERE) in EuroCOORD.
Impact of CD4 and CD8 dynamics and viral rebounds on loss of virological control in HIV controllers.
PLoS One.
Petrovas C, Ferrando-Martínez S, Gerner MY, Casazza JP, Pegu A, Deleage C, Cooper A, Hataye J, Andrews S, Ambrozak D, Del Río Estrada PM, Boritz E, Paris R, Moysi E, Boswell KL, Ruiz-Mateos E, Vagios I, Leal M, Ablanedo-Terrazas Y, Rivero A, González-Hernández LA, McDermott AB, Moir S, Reyes-Terán G, Docobo F, Pantaleo G, Douek DC, Betts MR, Estes JD, Germain RN, Mascola JR, Koup RA. S
Follicular CD8 T cells accumulate in HIV infection and can kill infected cells in vitro via bispecific antibodies.
ci Transl Med.
Rosado-Sánchez I, Herrero-Fernández I, Genebat M, Ruiz-Mateos E, Leal M, Pacheco YM.
Thymic Function Impacts the Peripheral CD4/CD8 Ratio of HIV-Infected Subjects.
Clin Infect Dis.
Herrero-Fernández I, Pacheco YM, Genebat M, Rodríguez-Méndez MDM, Lozano MDC, Polaino MJ, Rosado-Sánchez I, Tarancón-Díez L, Muñoz-Fernández MÁ, Ruiz-Mateos E, Leal M.
Association between a Suppressive Combined Antiretroviral Therapy Containing Maraviroc and the Hepatitis B Virus Vaccine Response.
Antimicrob Agents Chemother.